Nalls Sherbakoff Group, LLC Crispr Therapeutics Ag Transaction History
Nalls Sherbakoff Group, LLC
- $112 Billion
- Q4 2023
A detailed history of Nalls Sherbakoff Group, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Nalls Sherbakoff Group, LLC holds 7 shares of CRSP stock, worth $361. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7
Previous 7
-0.0%
Holding current value
$361
Previous $318,000
38.05%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
503Shares Held
57MCall Options Held
1.7MPut Options Held
1.8M-
Capital International Investors Los Angeles, CA7.87MShares$406 Million0.09% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.5MShares$387 Million3.35% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.97MShares$153 Million0.1% of portfolio
-
Nikko Asset Management Americas, Inc.2.97MShares$153 Million1.61% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$143 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.03B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....